Sedastart vet.
Active substance
ATC code
Species
Dog and Cat
Indications
In dogs and cats:
Sedation to facilitate handling. Premedication prior to general anaesthesia.
In cats:
In combination with ketamine for general anaesthesia for minor surgical procedures of short duration.
Dose to be administered and administration route
The veterinary medicinal product is intended for:
Dogs: Intramuscular or intravenous use.
Cats: Intramuscular use.
Use of an appropriately graduated syringe is recommended to ensure accurate dosing when administering small volumes
Dogs:
For sedation, the veterinary medicinal product should be administered at the rate of 750 μg medetomidine hydrochloride i.v. or 1000 μg medetomidine hydrochloride i.m. per square meter of body surface. Use the table below to determine the correct dosage on the basis of body weight:
Maximal effect is obtained within 15-20 minutes. Clinical effect is dosedependent, lasting from 30-180 minutes.
Dosages in ml and corresponding amount of medetomidine hydrochloride in μg/kg bw):
|
Body weight [kg] |
i.v. – Injection [ml] |
corresp. to [μg/kg bw] |
i.m. – Injection [ml] |
corresp. to [μg/kg bw] |
|
1 |
0.08 |
80.0 |
0.10 |
100.0 |
|
2 |
0.12 |
60.0 |
0.16 |
80.0 |
|
3 |
0.16 |
53.3 |
0.21 |
70.0 |
|
4 |
0.19 |
47.5 |
0.25 |
62.5 |
|
5 |
0.22 |
44.0 |
0.30 |
60.0 |
|
6 |
0.25 |
41.7 |
0.33 |
55.0 |
|
7 |
0.28 |
40.0 |
0.37 |
52.9 |
|
8 |
0.30 |
37.5 |
0.40 |
50.0 |
|
9 |
0.33 |
36.7 |
0.44 |
48.9 |
|
10 |
0.35 |
35.0 |
0.47 |
47.0 |
|
12 |
0.40 |
33.3 |
0.53 |
44.2 |
|
14 |
0.44 |
31.4 |
0.59 |
42.1 |
|
16 |
0.48 |
30.0 |
0.64 |
40.0 |
|
18 |
0.52 |
28.9 |
0.69 |
38.3 |
|
20 |
0.56 |
28.0 |
0.74 |
37.0 |
|
25 |
0.65 |
26.0 |
0.86 |
34.4 |
|
30 |
0.73 |
24.3 |
0.98 |
32.7 |
|
35 |
0.81 |
23.1 |
1.08 |
30.9 |
|
40 |
0.89 |
22.2 |
1.18 |
29.5 |
|
50 |
1.03 |
20.6 |
1.37 |
27.4 |
|
60 |
1.16 |
19.3 |
1.55 |
25.8 |
|
70 |
1.29 |
18.4 |
1.72 |
24.6 |
|
80 |
1.41 |
17.6 |
1.88 |
23.5 |
|
90 |
1.52 |
16.9 |
2.03 |
22.6 |
|
100 |
1.63 |
16.3 |
2.18 |
21.8 |
For premedication, the veterinary medicinal product should be administered at a dosage of 10-40 µg medetomidine hydrochloride per kg body weight, corresponding to 0.1 – 0.4 ml product per 10 kg body weight. The exact dose depends on the combination of drugs used and the dosage(s) of the other drug(s). The dose should furthermore be adjusted to the type of surgery, length of procedure and patient temperament and weight. Premedication with medetomidine will significantly reduce the dosage of the induction agent required and will reduce volatile anaesthetic requirements for maintenance anaesthesia. All anaesthetic agents used for induction or maintenance of anaesthesia should be administered to effect. Before using any combinations, product literature for the other products should be observed. See also section 4.5.
Cats:
For moderate-deep sedation and restraint of cats the veterinary medicinal product should be administered at a dosage of 50 – 150 μg medetomidine hydrochloride / kg bw (corresp. to 0.05 – 0.15 ml product / kg bw).
For anaesthesia the veterinary medicinal product should be administered at a dosage of 80 μg medetomidine hydrochloride / kg bw (corresp. to 0.08 ml product / kg bw) and 2.5 to 7.5 mg ketamine / kg bw. Using this dosage anaesthesia occurs within 3 – 4 minutes and is apparent for 20 – 50 minutes.
For longer lasting procedures administration has to be repeated by using ½ of the initial dose (i.e. 40 μg medetomidine hydrochloride (corresp. to 0.04 ml product / kg bw) and 2.5 – 3.75 mg ketamine / kg bw) or 3.0 mg ketamine / kg bw alone. Alternatively, for longer lasting procedures anaesthesia may be extended by use of the inhalation agents isoflurane or halothane, with oxygen or oxygen/nitrous oxide. See section 4.5
Adverse reactions
Bradycardia with atrioventricular block (1st and 2nd degree) and occasionally extrasystolia. Vasoconstriction of coronary artery. Decreased cardiac output.
Blood pressure will increase initially after administration and then return to normal, or slightly below normal. In rare cases, pulmonary oedema has been reported, especially in cats. Death from circulatory failure with severe congestion of the lungs, liver, or kidney has been reported.
Respiratory depression may occur, cyanosis.
In circulatory and respiratory depression manual ventilation and an oxygen supplement may be indicated. Atropine may increase the cardiac rate.
Some dogs and most cats will vomit within 5-10 minutes of injection. Cats may also vomit on recovery. Sensitivity to loud noises is observed in some individuals.
Increased diuresis. Hypothermia. Pain at injection site and muscle tremor may be seen. In individual cases reversible hyperglycaemia due to depression of insulin secretion.
Dogs with a body weight of less than 10 kg may show the undesirable effects mentioned above more often.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 19994/5009 |
Similar products
Showing 4 of 4 results
Sedastart vet.
Sedastart vet.
Sedastart vet.
